Treatment of Avascular Necrosis
Treatment of avascular necrosis is stage-dependent: early-stage disease (Ficat I-II with <30% necrotic volume and preserved articular surface) should be managed with core decompression augmented with bone marrow aspirate concentrate (BMAC), while late-stage disease (Ficat III-IV with articular collapse) requires total joint arthroplasty. 1
Stage-Based Treatment Algorithm
Early-Stage Disease (Ficat I-II, No Articular Collapse)
Surgical intervention with core decompression plus BMAC augmentation is the preferred approach for early AVN, as this combination demonstrates superior survivorship from total hip arthroplasty (69.4% at 120 months) compared to non-augmented procedures (48.5%) 2. The evidence specifically supports BMAC over other orthobiologics—while bone marrow mesenchymal stromal cells (BM-MSCs), platelet-rich plasma (PRP), and intra-arterial approaches showed statistical benefits in pooled analysis, only BMAC demonstrated clear superiority when directly compared to controls 2.
Key prognostic factors that determine treatment success:
- Necrotic volume <30% has <5% progression to collapse versus 46-83% progression when >30% 1
- For humeral head AVN, necrotic angle <90° predicts no collapse at 24 months 1
- Age >40 years, increased BMI (>24 kg/m²), joint effusion, and bone marrow edema increase collapse risk 1
Core decompression can be supplemented with vascularized fibular grafting or autologous bone marrow cells, though the overall efficacy at preventing eventual collapse remains controversial 1. Recent data from 2025 suggests vascularized bone transfers should be offered primarily to younger patients 3.
Noninvasive Therapies (Limited Supporting Data)
The 2022 ACR guidelines note that noninvasive therapies have gained only limited supporting data, including statins, bisphosphonates, anticoagulants, extracorporeal shock wave therapy, and hyperbaric oxygen 1. These should not be relied upon as primary treatment for preventing articular collapse.
Common pitfall: Do not delay surgical intervention in early-stage disease waiting for noninvasive therapies to work—early surgical prevention is critical to avoid articular collapse and eventual joint replacement 1.
Late-Stage Disease (Ficat III-IV, With Articular Collapse)
Total joint arthroplasty is the definitive treatment for late-stage AVN with articular collapse and secondary osteoarthritis 1. Resurfacing hemiarthroplasty may be considered for isolated femoral or humeral head collapse without severe secondary osteoarthritis 1.
For talar AVN with collapse, talar resection/replacement with arthroplasty or tibiotalar joint fusion is performed 1.
Important context: Femoral head osteonecrosis accounts for 10% of all total hip replacement indications in the United States 1.
Location-Specific Considerations
AVN most commonly affects the femoral head (68% in steroid-treated patients), but multifocal disease occurs frequently, involving knee (44%), ankle (17%), and shoulder (15%) 1. In nontraumatic cases, femoral head osteonecrosis is bilateral in 70-80% of cases 1—always image the contralateral hip even if asymptomatic.
For humeral head AVN, treatment options parallel those for the femoral head: arthroscopic debridement, core decompression, vascularized bone grafts for early disease, and shoulder arthroplasty for advanced collapse 4.
Critical Nuances
The controversy around core decompression efficacy 1 is resolved by the 2025 systematic review showing that augmentation with orthobiologics—specifically BMAC—significantly improves outcomes 2. Core decompression alone has questionable efficacy; augmentation is essential.
Epiphyseal versus metadiaphyseal AVN: Only epiphyseal osteonecrosis leads to subchondral fracture and secondary osteoarthritis, explaining why metadiaphyseal cases lack long-term sequelae and may not require aggressive intervention 1.
Risk Factor Management
Address modifiable risk factors including corticosteroid therapy, alcohol use, and hypercholesterolemia 4, 5. However, this is adjunctive—the necrotic bone will not revascularize through risk factor modification alone once AVN is established.